ERT Announces Availability of Insights Cloud
ERT announced the launch of the Insights Cloud™, a suite of data analytics, visualization, and workflow applications.
ERT announced the launch of the Insights Cloud™, a suite of data analytics, visualization, and workflow applications. EXPERT Central™ - ERT's proprietary Research & Integration platform, includes an eClinical data hub for integrating and harmonizing clinical trials data from any clinical system. The integration framework includes standard adapters to leading electronic data capture (EDC) solutions such as Medidata Rave® and Oracle InForm®, and facilitates the real-time exchange of clinical trials data. This builds on ERT's acquisition of eClinical Insights in 2014.
The ERT Insights Cloud now offers site selection, risk-based management, and enhanced performance measurement.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
